BioSpace News Archive

Hepion Pharmaceuticals, Inc. today announced that Dr. Robert Foster, will present virtually at the H.C. Wainwright 4 th Annual NASH Conference on Monday, October 5, 2020 at 4:00 p.m. E.T.

A total of 6 products from the Lorient product line of cross-linked hyaluronic acid dermal fillers developed by Joonghun Pharmaceutical (CEO Sukjoon Yoon) have received the CE mark. Lorient is a premium cross-linked hyaluronic dermal filler that has established a foothold for entry into the European beauty market by proving the safety and quality suitable for global standards through the acquisition of this European certification. Lorie

Additional education and training sets orthodontists apart from general dentists when it comes to treatment expertise and understanding of tooth movement.

Limitless Venture Group, Inc. (“LVGI” or “the Company”) today announced it has generated record revenues for the fiscal year 2020, July 1, 2019 through June 30, 2020.

AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing.

ProciseDx Inc. has established distribution agreements with two new distributors in Europe: BHR Pharmaceuticals Ltd in the United Kingdom and D.I.D Diagnostic International Distribution S.p.A. in Italy.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the outcome of the pre-planned interim analysis for the Phase 3 RELIEF study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia.

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2020 after market close on Wednesday, October 28, 2020 at 4:30 PM Eastern Time. Penumbra is hosting its call in advance of Election Day 2020, which will be a paid company holiday for Penumbra’s U

- Company to Proceed with Rolling NDA Submission following Recent Pre-NDA Meeting with FDA - - Rolling NDA Expected to Commence in the Fourth Quarter of 2020 - - Completion of NDA Submission Expected in First Quarter 2021 - - Company to Host Conference Call on Wednesday, September 30 at 8:30 AM ET - [29-September-2020] SEATTLE , Sept. 29,